Novel therapies for an old virus: Treatment of RSV infections in the 21st century

Expert Review of Anti-Infective Therapy

Volumn 7, Issue 9, 2009, Pages 1125-1129

  Lüsebrink, Jessica ^a   Schildgen, Verena ^a   Schildgen, Oliver ^b  

^a UNIVERSITY OF BONN   (Germany)

^b Institut für Pathologie   (Germany)

Author keywords

Children; Clinical trials; Drugs; Elderly; High risk patients; RSV; Treatment

Indexed keywords

1 CYCLOPROPYL 1,3 DIHYDRO 3 [[1 (4 HYDROXYBUTYL) 1H BENZIMIDAZOL 2 YL]METHYL] 2H IMIDAZO[4,5 C]PYRIDIN 2 ONE; 2 [[2 [[1 (2 AMINOETHYL) 4 PIPERIDINYL]AMINO] 4 METHYL 1H BENZIMIDAZOL 1 YL]METHYL] 6 METHYL 3 PYRIDINOL; ALN RSV 01; AMITIVIR; ANTIVIRUS AGENT; MBX 300; MERIMEPODIB; PALIVIZUMAB; PYRAMICIN; RESPIRATORY SYNCYTIAL VIRUS ANTIBODY; RFI 641; RIBAVIRIN; RSV 604; TARIBAVIRIN; TMC 353121; UNCLASSIFIED DRUG; VIRUS VACCINE; VP 14637;

BRONCHIOLITIS; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HIGH RISK PATIENT; HOSPITALIZATION; HUMAN; IMMUNIZATION; LOWER RESPIRATORY TRACT INFECTION; NONHUMAN; PNEUMONIA; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; REVIEW; TREATMENT DURATION; VIRAL UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION;

ANTIGENS, CD14; ANTIVIRAL AGENTS; BENZIMIDAZOLES; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; GLYCOSAMINOGLYCANS; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; RNA, SMALL INTERFERING; VIRAL FUSION PROTEINS; VIRUS ATTACHMENT; VIRUS REPLICATION;

EID: 73949093089     PISSN: 14787210     EISSN: 17448336     Source Type: Journal    
DOI: 10.1586/ERI.09.90     Document Type: Review

References (53)

1. Smyth RL, Openshaw PJ. Bronchiolitis. Lancet 368 (9532), 312-322 (2006).
2. Paramore LC, Ciuryla V, Ciesla G, Liu L. Economic impact of respiratory syncytial virus-related illness in the US: an analysis of national databases. Pharmacoeconomics 22 (5), 275-284 (2004).
3. Simon A, Khurana K, Wilkesmann A et al. Nosocomial respiratory syncytial virus infection: impact of prospective surveillance and targeted infection control. Int. J. Hyg. Environ. Health 209 (4), 317-324 (2006).
4. Simon A, Muller A, Khurana K et al. Nosocomial infection: a risk factor for a complicated course in children with respiratory syncytial virus infection - results from a prospective multicenter German surveillance study. Int. J. Hyg. Environ. Health 211 (3-4), 241-250 (2008).
5. von RA, Schildgen O, Klinkenberg D, Muller A, von MA, Simon A. Respiratory syncytial virus infection in children admitted to hospital but ventilated mechanically for other reasons. J. Med. Virol. 81 (1), 160-166 (2009).
6. Wilkesmann A, Ammann RA, Schildgen O et al. Hospitalized children with respiratory syncytial virus infection and neuromuscular impairment face an increased risk of a complicated course. Pediatr. Infect. Dis. J. 26 (6), 485-491 (2007).
7. Meissner HC, Long SS. Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections. Pediatrics 112 (6 Pt 1), 1447-1452 (2003).
8. Hoffmann SH, Staffa JA, Smith RA, Craig DK, Parker G. Inhalation toxicity of ribavirin in suckling ferrets. J. Appl. Toxicol. 7 (5), 343-351 (1987).
9. Hoffmann SH, Wade MJ, Staffa JA, McGregor DB, Holmstrom M, Dayan AD. Dominant lethal study of ribavirin in male rats. Mutat. Res. 188 (1), 29-34 (1987).
10. Krilov LR, Mandel FS, Barone SR, Fagin JC. Follow-up of children with respiratory syncytial virus bronchiolitis in 1986 and 1987: potential effect of ribavirin on long term pulmonary function. The Bronchiolitis Study Group. Pediatr. Infect. Dis. J. 16 (3), 273-276 (1997).
11. Krilov LR. Safety issues related to the administration of ribavirin. Pediatr. Infect. Dis. J. 21 (5), 479-481 (2002).
12. Sidwell RW, Barnard DL. Respiratory syncytial virus infections: recent prospects for control. Antiviral Res. 71 (2-3), 379-390 (2006).
13. Kurt-Jones EA, Popova L, Kwinn L et al. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1 (5), 398-401 (2000).
14. Tripp RA, Jones LP, Haynes LM, Zheng H, Murphy PM, Anderson LJ. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2 (8), 732-738 (2001).
15. Villar E, Barroso IM. Role of sialic acid-containing molecules in paramyxovirus entry into the host cell: a minireview. Glycoconj. J. 23 (1-2), 5-17 (2006).
16. Kimura K, Ishioka K, Hashimoto K et al. Isolation and characterization of NMSO3-resistant mutants of respiratory syncytial virus. Antiviral Res. 61 (3), 165-171 (2004).
17. Kimura K, Mori S, Tomita K et al. Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo. Antiviral Res. 47 (1), 41-51 (2000).
18. Cianci C, Genovesi EV, Lamb L et al. Oral efficacy of a respiratory syncytial virus inhibitor in rodent models of infection. Antimicrob. Agents Chemother. 48 (7), 2448-2454 (2004).
19. Cianci C, Yu KL, Combrink K et al. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents Chemother. 48 (2), 413-422 (2004).
20. Cianci C, Langley DR, Dischino DD et al. Targeting a binding pocket within the trimer-of-hairpins: small-molecule inhibition of viral fusion. Proc. Natl Acad. Sci. USA 101 (42), 15046-15051 (2004).
21. Razinkov V, Huntley C, Ellestad G, Krishnamurthy G. RSV entry inhibitors block F-protein mediated fusion with model membranes. Antiviral Res. 55 (1), 189-200 (2002).
22. Huntley CC, Weiss WJ, Gazumyan A et al. RFI-641, a potent respiratory syncytial virus inhibitor. Antimicrob. Agents Chemother. 46 (3), 841-847 (2002).
23. Weiss WJ, Murphy T, Lynch ME et al. Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. J. Med. Primatol. 32 (2), 82-88 (2003).
24. Informa UK Ltd. Pharmaprojects - Pharmaceutical Research & Development Pipeline Intelligence [computer program] (2008).
25. Douglas JL, Panis ML, Ho E et al. Small molecules VP-14637 and JNJ-2408068 inhibit respiratory syncytial virus fusion by similar mechanisms. Antimicrob. Agents Chemother. 49 (6), 2460-2466 (2005).
26. Wyde PR, Laquerre S, Chetty SN, Gilbert BE, Nitz TJ, Pevear DC. Antiviral efficacy of VP14637 against respiratory syncytial virus in vitro and in cotton rats following delivery by small droplet aerosol. Antiviral Res. 68 (1), 18-26 (2005).
27. Wyde PR, Chetty SN, Timmerman P, Gilbert BE, Andries K. Short duration aerosols of JNJ 2408068 (R170591) administered prophylactically or therapeutically protect cotton rats from experimental respiratory syncytial virus infection. Antiviral Res. 60 (3), 221-231 (2003).
28. Bonfanti JF, Meyer C, Doublet F et al. Selection of a respiratory syncytial virus fusion inhibitor clinical candidate. 2. Discovery of a morpholinopropylaminobenzimidazole derivative (TMC353121). J. Med. Chem. 51 (4), 875-896 (2008).
29. Lai SH, Stein DA, Guerrero-Plata A et al. Inhibition of respiratory syncytial virus infections with morpholino oligomers in cell cultures and in mice. Mol. Ther. 16 (6), 1120-1128 (2008).
30. Stein D, Foster E, Huang SB, Weller D, Summerton J. A specificity comparison of four antisense types: morpholino, 2'-O-methyl RNA, DNA, and phosphorothioate DNA. Antisense Nucleic Acid Drug Dev. 7 (3), 151-157 (1997).
31. Summerton J, Stein D, Huang SB, Matthews P, Weller D, Partridge M. Morpholino and phosphorothioate antisense oligomers compared in cell-free and in-cell systems. Antisense Nucleic Acid Drug Dev. 7 (2), 63-70 (1997).
32. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 7 (3), 187-195 (1997).
33. De CE, Cools M, Balzarini J et al. Antiviral activities of 5-ethynyl-1-β-dribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob. Agents Chemother. 35 (4), 679-684 (1991).
34. Markland W, McQuaid TJ, Jain J, Kwong AD. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with a interferon. Antimicrob. Agents Chemother. 44 (4), 859-866 (2000).
35. McHutchison JG, Shiffman ML, Cheung RC et al. A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-α in previously untreated patients with chronic hepatitis C. Antivir. Ther. 10 (5), 635-643 (2005).
36. Gabrielsen B, Phelan MJ, Barthel-Rosa L et al. Synthesis and antiviral evaluation of N-carboxamidine-substituted analogues of 1-β-d-ribofuranosyl-1, 2, 4-triazole-3-carboxamidine hydrochloride. J. Med. Chem. 35 (17), 3231-3238 (1992).
37. Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF. In vitro and in vivo influenza virus-inhibitory effects of viramidine. Antiviral Res. 68 (1), 10-17 (2005).
38. Wyde PR, Ambrose MW, Meyer HL, Gilbert BE. Toxicity and antiviral activity of LY253963 against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antiviral Res. 14 (4-5), 237-247 (1990).
39. Hayden FG, Tunkel AR, Treanor JJ, Betts RF, Allerheiligen S, Harris J. Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans. Antimicrob. Agents Chemother. 38 (5), 1178-1181 (1994).
40. Herman JL, Chay SH. Quantitative whole-body autoradiography in pregnant rabbits to determine fetal exposure of potential teratogenic compounds. J. Pharmacol. Toxicol. Methods 39 (1), 29-33 (1998).
41. DeVincenzo J, Cehelsky JE, Alvarez R et al. Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res. 77 (3), 225-231 (2008).
42. Bitko V, Musiyenko A, Shulyayeva O, Barik S. Inhibition of respiratory viruses by nasally administered siRNA. Nat. Med. 11 (1), 50-55 (2005).
43. Polack FP, Karron RA. The future of respiratory syncytial virus vaccine development. Pediatr. Infect. Dis. J. 23 (1 Suppl.), S65-S73 (2004).
44. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60. Vaccine 14 (13), 1214-1218 (1996).
45. Falsey AR, Walsh EE. Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly. Vaccine 15 (10), 1130-1132 (1997).
46. Munoz FM, Piedra PA, Glezen WP. Safety and immunogenicity of respiratory syncytial virus purified fusion protein-2 vaccine in pregnant women. Vaccine 21 (24), 3465-3467 (2003).
47. Groothuis JR, King SJ, Hogerman DA, Paradiso PR, Simoes EA. Safety and immunogenicity of a purified F protein respiratory syncytial virus (PFP-2) vaccine in seropositive children with bronchopulmonary dysplasia. J. Infect. Dis. 177 (2), 467-469 (1998).
48. Piedra PA, Cron SG, Jewell A et al. Immunogenicity of a new purified fusion protein vaccine to respiratory syncytial virus: a multi-center trial in children with cystic fibrosis. Vaccine 21 (19-20), 2448-2460 (2003).
49. Ison MG, Mills J, Openshaw P, Zambon M, Osterhaus A, Hayden F. Current research on respiratory viral infections: Fourth International Symposium. Antiviral Res. 55 (2), 227-278 (2002).
50. Power UF, Plotnicky-Gilquin H, Huss T et al. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment. Virology 230 (2), 155-166 (1997).
51. Power UF, Nguyen TN, Rietveld E et al. Safety and immunogenicity of a novel recombinant subunit respiratory syncytial virus vaccine (BBG2Na) in healthy young adults. J. Infect. Dis. 184 (11), 1456-1460 (2001).
52. Wright PF, Karron RA, Belshe RB et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J. Infect. Dis. 182 (5), 1331-1342 (2000).
53. Wright PF, Karron RA, Madhi SA et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J. Infect. Dis. 193 (4), 573-581 (2006).